XYLB

Across TCGA pan-cancer cohorts, XYLB mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated XYLB data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher XYLB mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated XYLB expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where XYLB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.295	0.927	<.001	17	view →
CCRCC	OS	Tertile	All	1.000	0.585	.007	12	view →
GBM	DFS	Tertile	All	0.314	0.487	.013	6	view →
HNSC	OS	Tertile	All	0.608	0.808	.039	2	view →
LSCC	OS	Median	II,III,IV	0.885	0.677	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

XYLB–PDAC (DFS)

Open the PDAC breakdown →